Cargando…

PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis

Therapies that targeted PD-1 have shown remarkable rates of durable clinical responses in patients with various tumor types. However, the extent and knowledge of pulmonary toxicities associated with PD-1 blockade, mainly manifested as pneumonitis, remains obscure. In this study, a total of 6360 subj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jiaying, Hong, Dongsheng, Zhang, Xiangnan, Lu, Xiaoyang, Miao, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341153/ https://www.ncbi.nlm.nih.gov/pubmed/28272463 http://dx.doi.org/10.1038/srep44173

Ejemplares similares

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
por: Huang, Yafang, et al.
Publicado: (2019)

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
por: Balaji, Aanika, et al.
Publicado: (2021)

Correction: Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
Publicado: (2022)

Correction: Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
Publicado: (2023)

The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
por: Ma, Ke, et al.
Publicado: (2018)

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
por: Hong, Dongsheng, et al.
Publicado: (2017)

TIGAR alleviates oxidative stress in brain with extended ischemia via a pentose phosphate pathway-independent manner
por: Liu, Mengru, et al.
Publicado: (2022)

Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis
por: Cui, Peng-Fei, et al.
Publicado: (2017)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)

Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature
por: Liang, Xiuju, et al.
Publicado: (2019)

The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs)
por: Long, Yi-Xiu, et al.
Publicado: (2022)

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
por: Yin, Jianqiong, et al.
Publicado: (2022)

Clinical Management of Pneumonitis in Patients Receiving Anti–PD-1/PD-L1 Therapy
por: Bala-Hampton, Justin E., et al.
Publicado: (2018)

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Dosiomics: Extracting 3D Spatial Features From Dose Distribution to Predict Incidence of Radiation Pneumonitis
por: Liang, Bin, et al.
Publicado: (2019)

Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta‐analysis
por: Qie, Wenting, et al.
Publicado: (2023)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Pneumonitis after Stereotactic Thoracic Radioimmunotherapy with Checkpoint Inhibitors: Exploration of the Dose–Volume–Effect Correlation
por: Kraus, Kim Melanie, et al.
Publicado: (2022)

Acute exacerbation of fibrotic hypersensitivity pneumonitis: incidence and outcomes
por: Kang, Jieun, et al.
Publicado: (2021)

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
por: Teng, Feifei, et al.
Publicado: (2020)

Angiotensin-converting Enzyme Inhibitors Decrease the Incidence of Radiation-induced Pneumonitis Among Lung Cancer Patients: A Systematic Review and Meta-analysis
por: Sun, Fengze, et al.
Publicado: (2018)

A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors
por: Yakymenko, Dorthe, et al.
Publicado: (2023)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Acute Low-Dose Hydralazine-Induced Lupus Pneumonitis
por: Holman, Sarah K., et al.
Publicado: (2017)

Cyclooxygenase-2 inhibitors modulate skin aging in a catalytic activity-independent manner
por: Lee, Mi Eun, et al.
Publicado: (2012)

Prognostic significance of the radiologic features of pneumonitis induced by anti‐PD‐1 therapy
por: Watanabe, Satoshi, et al.
Publicado: (2020)

Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner
por: Long, Yiru, et al.
Publicado: (2023)

Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
por: Miao, Kang, et al.
Publicado: (2021)

TNF-α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice
por: Gao, Jian, et al.
Publicado: (2022)

Further Notes on the Incidence of Pneumonic Plague Cases in Gaya (Bihar)
por: Seal, S. C., et al.
Publicado: (1949)

Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis
por: Zhang, Xi, et al.
Publicado: (2016)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
por: Su, Qiang, et al.
Publicado: (2019)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
por: Tonk, Erwin H.J., et al.
Publicado: (2019)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
por: Liu, Jia, et al.
Publicado: (2022)

Pneumonitis
por: Napier, L. Everard, et al.
Publicado: (1942)

Pneumonitis
Publicado: (1911)

Cannot write session to /tmp/vufind_sessions/sess_169mcvio53sgcbhba6r1bffb7c